The multistakeholder meeting on perinatal asphyxia, organized by the IMIconect4chilcren (c4c) entity will take place from 18.-19. September 2023 in Rome (and virtually). The meeting will be a hybrid, ahead of the 5th jENS (joint European Neonatal Societies). The meeting will be on invitation only, following expression of interest. International academic experts in perinatal asphyxia and neonatal preclinical research, representatives from pharmaceutical companies developing relevant assets, representatives from regulators (EMA, FDA) and patients, parents and their advocates can attend. Therefore, please apply by filling an Expression of Interest also available in the attached document (Deadline: 30 July).
More information about the meeting is available in the attached document below.
The society celebrated its 35th anniversary and 20th conference from 28-30 June in Prague hosted by president Pavla Pokorna. The meeting was success with a broad scientific program and a one-day pre-conference workshop on principles of neonatal and pediatric clinical pharmacology. This was accompanied by wonderful evening programs with classical concerts in the parliament and the Rudolfinum.
Slides, posters, abstracts as well as all photos will be provided in our "Members Only" area - have a look!
The society informs about the new secretary general:
Robert Flint is a hospital pharmacist in the Erasmus MC - Sophia Children's Hospital with special focus on intensive care neonatology and obstetrics. His research aims to improve pharmacotherapy in (premature) neonates and around pregnancy using population pharmacokinetic-pharmacodynamic models leading to optimized dosing recommendations. Furthermore, Robert aims to bring the position of therapeutic drug monitoring to a higher level in clinical care. This includes a more extensive use of Bayesian forecasting to suggest the personalized starting dose as well as the next step of incorporating model informed precision dosing in pediatrics.
This guidance is intended to assist sponsors of investigational new drug applications and applicants of new drug applications, biologics license applications and supplements to such applications who are planning to conduct clinical studies in neonatal populations.
This guidance provides recommendations for neonatal clinical pharmacology studies and will be useful for education and practice.
Additional tools (graphical snapshot, podcasts) can be found here:
IUPHAR is responding to the current crisis by coordinating pharmacological resources worldwide. Although most of the current research is done in adults, we believe
in part it may be relevant for pediatric pharmacologists as well.
Based in Ghent, Belgium, ESDPPP promotes research in developmental perinatal and paediatric pharmacology and offers a forum for dialogue between pharmacologists, clinicians, and scientists interested in the effect of medicines on the developing fetus, infant, and child.
The ESDPPP celebrated its 35th anniversary in 2023. This milestone provides an important opportunity to celebrate ESDPPP’s achievements to date and to describe our future aspirations and ambitions on behalf of millions of paediatric patients worldwide.
We aim to improve medicines for children and advance research and global access to paediatric medicines. We also advocate politically for the continued development of safe, evidence-based medications for children. In this respect, ESDPPP works closely with European Medicines Agency (EMA), International Union of Basic and Clinical Pharmacology (IUPHAR) and the World Health Organization (WHO).
Meeting our colleagues is very important for our society. We enjoyed a wonderful congress in Prague, CZ, in June 2023 and are looking forward to our next congress, which will be held in Nijemegen (2025). We highly welcome your idea and suggestion for this event.
Join us on LinkedIn!!
We want to use LinkedIn for announcements and discussions in our field. Please check out our group page on LinkedIn and become a group member.
The official journal of the ESDPPP is the leading paediatric journal Archives of Disease in Childhood. It contains a Drug Therapy section which is published every 3 months.
ESDPPP is associated with a range of organizations like EMEA, IUHAR and WHO. Additional information on projects, initiatives and conferences will be available within short.
In 2023 ESDPPP celebrated its 35th anniversary at the society's 20th conference in Prague, CZ. The meeting will be hosted by our new president Pavla Pokorna.
After the congress ...
Our last congress in Prague was a great success and a meeting place for many. Did you enjoy it as well? Become a member of ESDPPP and be the first to know more about the next congress in the Netherlands.
ESDPPP VZW p/a University Hospital
Gasthuisberg Herestraat 49
The primary aim of the society is to promote research in the field of paediatric pharmacology and to offer a forum for exchange between pharmacologists and clinical physicians about more adequate drug administration.
Join us on LinkedIn